Compare iShares MSCI Germany (DAX) (EWG) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Germany (DAX) vs Summit Therapeutics Inc — how do they compare? iShares MSCI Germany (DAX) trades at $41.16, while Summit Therapeutics Inc trades at $13.71 (market cap $11.70B). The key difference: iShares MSCI Germany (DAX) is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| EWG | SMMT | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $44.56 | $29.32 |
52-Week Low | $38.08 | $13.05 |
Market Cap | — | $11.70B |
Enterprise Value | — | $11.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWG is trading at $41.19, down 0.48% on the day with a neutral technical signal. The stock shows mixed technical indicators with bearish moving averages but oversold RSI conditions. Recent German economic developments, including a €13.3 billion energy relief package and healthcare reforms, create a complex backdrop for this US-listed German-focused ETF.
The outlook remains balanced with European monetary policy uncertainty and energy market volatility presenting both opportunities and risks. German fiscal support measures could provide stability, while ECB rate decisions and Middle East tensions may drive near-term volatility in European markets.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Germany (DAX)
EWG is a country-specific ETF that tracks the performance of the German equity market. It provides exposure to large and mid-sized companies in Germany across key sectors like industrials and financials, with top holdings such as SAP, Siemens, and Allianz.
Read more on EWG →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
